Perspective Therapeutics insider purchase: 9,498 shares at $2.10

Rhea-AI Filing Summary

Perspective Therapeutics (CATX) director Robert F. Williamson, III reported a Form 4 purchase of common stock. On 11/12/2025, he bought 9,498 shares (transaction code P) at $2.10 per share.

Following the transaction, the filing shows 9,864 shares held indirectly via the RFW3 Revocable Trust and 108,982 shares held directly. This reflects insider open-market buying and updates his reported holdings.

Insider Trade Summary

Net Buyer: 9,498 shares ($19,946)

Net Buy 2 txns

Insider Williamson Robert F III

Role Director

Bought 9,498 shs ($20K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	9,498	$2.10	$20K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 9,864 shares (Indirect, RFW3 Revocable Trust); Common Stock — 108,982 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williamson Robert F III

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/12/2025		P		9,498	A	$2.1	9,864	I	RFW3 Revocable Trust
Common Stock								108,982	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Robert F. Williamson, III by Chris Nenno, as Attorney-in-Fact	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CATX report?

A director, Robert F. Williamson, III, reported buying 9,498 CATX common shares at $2.10 on 11/12/2025.

What was the price paid for the CATX shares?

The purchase price reported was $2.10 per share.

How many CATX shares does the director now hold indirectly?

The filing lists 9,864 shares held indirectly through the RFW3 Revocable Trust.

How many CATX shares are held directly by the director?

The filing shows 108,982 shares held directly.

What is the transaction code on the Form 4?

The transaction code is P, indicating an open-market or private purchase of non-derivative securities.

What type of security was involved?

The transaction involved Common Stock of Perspective Therapeutics, Inc. (CATX).

Was this filing made by one reporting person?

Yes. The form indicates it was filed by one reporting person.